← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06734572
NCT06734572 18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT06734572 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Malignant Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2024-06-25 |
| Primary Completion | 2025-10-01 |
Trial Parameters
Condition Malignant Neoplasm
Sponsor First Affiliated Hospital of Fujian Medical University
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 5
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-06-25
Completion 2025-10-01
Interventions
18F-FAPIBiotin
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
Eligibility Criteria
Inclusion Criteria: * Various solid tumors with available histopathological findings • Signed informed consent Exclusion Criteria: * pregnant or lactational women • who suffered from severe hepatic and renal insufficiency
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology